

Can the FDA Salvage Interchangeable Follow-On Biologics?

PUBLICATIONS | LESS THAN 1 MIN READ


November 19, 2019

By: Ted Mathias

BioProcess Online / Biosimilar Development

BioProcess Online and *Biosimilar Development* published “Can the FDA Salvage Interchangeable Follow-On Biologics?”, an article co-written by Axinn partner Ted Mathias.

Related People



Ted Mathias

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
AXINN VIEWPOINTS LITIGATION & TRIALS